

TABLE 159: GENOTYPE 1B TREATMENT-NAIVE WITH EMERGING TREATMENTS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR48	1.58 (0.40 to 2.09)	31.10 (–33.98 to 50.27)
SOF12 + LDV12		1.83 (1.57 to 2.19)	44.52 (35.43 to 53.15)
SOF8 + LDV8 + RBV8		1.75 (0.97 to 2.13)	40.83 (–1.28 to 51.73)
SOF12 + LDV12 + RBV12		1.82 (1.56 to 2.17)	43.84 (34.67 to 52.60)
SOF24 + LDV24 + RBV24		1.83 (1.57 to 2.19)	44.46 (35.35 to 53.36)
T12 PR24-48 RGT q8		1.53 (1.26 to 1.80)	28.37 (14.18 to 38.30)
T12 PR24-48 RGT q12		1.57 (1.20 to 1.90)	30.90 (10.88 to 42.32)
T12 PR48 q8		0.92 (0.16 to 1.82)	–4.23 (–48.77 to 39.73)
SIM12 PR24-48 RGT		1.59 (1.39 to 1.86)	31.80 (23.06 to 39.99)
SOF24 + RBV (low dose) 24		1.52 (0.30 to 2.07)	28.14 (–39.93 to 49.83)
PAR/RIT12 + OMB12 + DAS12		1.82 (1.44 to 2.19)	43.91 (24.96 to 53.73)
DCV24 + ASU24		1.71 (1.48 to 2.02)	38.17 (29.65 to 46.26)
SOF12 + PR12		1.53 (0.53 to 1.98)	29.01 (–24.98 to 46.68)
B44 PR48		1.38 (0.71 to 1.92)	20.83 (–15.87 to 43.88)
B24 PR28-48 RGT		1.43 (1.14 to 1.71)	23.04 (7.38 to 34.74)
GRZ12 + ELB12		1.84 (1.57 to 2.20)	44.78 (35.82 to 53.47)
DCV12 + ASU12 + BEC12 + RBV12		1.65 (0.46 to 2.08)	36.20 (–28.42 to 50.44)
DCV12 + ASU12 + BEC12		1.80 (1.54 to 2.15)	42.98 (33.26 to 52.06)
GRZ12 + ELB12 (50 mg q.d.)		1.67 (0.65 to 2.14)	36.56 (–19.78 to 51.94)
SOF12 + LDV12	SOF24 + RBV24	1.16 (0.98 to 4.17)	13.33 (–1.83 to 74.37)
SOF8 + LDV8 + RBV8		1.10 (0.59 to 4.02)	8.58 (–37.57 to 71.71)
SOF12 + LDV12 + RBV12		1.15 (0.97 to 4.18)	12.47 (–2.73 to 74.56)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + LDV24 + RBV24		1.16 (0.99 to 4.20)	13.30 (-1.24 to 74.83)
T12 PR24-48 RGT q8		0.97 (0.74 to 3.57)	-2.72 (-24.51 to 59.90)
T12 PR24-48 RGT q12		1.00 (0.72 to 3.59)	-0.36 (-25.49 to 61.26)
T12 PR48 q8		0.63 (0.12 to 1.99)	-30.15 (-82.00 to 33.56)
SIM12 PR24-48 RGT		1.01 (0.82 to 3.77)	0.71 (-17.35 to 65.41)
SOF24 + RBV (low dose) 24		0.98 (0.49 to 1.35)	-1.77 (-29.53 to 17.62)
PAR/RIT12 + OMB12 + DAS12		1.15 (0.89 to 4.14)	12.33 (-10.38 to 73.62)
DCV24 + ASU24		1.08 (0.90 to 3.95)	6.97 (-9.34 to 69.26)
SOF12 + PR12		0.99 (0.34 to 3.49)	-1.17 (-58.97 to 61.22)
B44 PR48		0.91 (0.44 to 3.04)	-7.96 (-52.32 to 53.06)
B24 PR28-48 RGT		0.91 (0.66 to 3.40)	-7.79 (-32.26 to 56.36)
GRZ12 + ELB12		1.16 (0.99 to 4.21)	13.48 (-0.95 to 75.21)
DCV12 + ASU12 + BEC12 + RBV12		1.04 (0.31 to 3.34)	3.77 (-57.59 to 62.58)
DCV12 + ASU12 + BEC12		1.14 (0.96 to 4.11)	11.56 (-3.84 to 72.92)
GRZ12 + ELB12 (50 mg q.d.)		1.06 (0.45 to 3.97)	5.14 (-49.36 to 69.75)
SOF8 + LDV8 + RBV8	SOF12 + LDV12	0.98 (0.52 to 1.02)	-2.23 (-46.52 to 1.65)
SOF12 + LDV12 + RBV12		0.99 (0.95 to 1.03)	-0.51 (-5.06 to 2.96)
SOF24 + LDV24 + RBV24		1.00 (0.96 to 1.05)	-0.17 (-3.46 to 4.42)
T12 PR24-48 RGT q8		0.84 (0.68 to 0.93)	-15.89 (-31.24 to -6.48)
T12 PR24-48 RGT q12		0.87 (0.65 to 0.97)	-13.25 (-34.37 to -3.29)
T12 PR48 q8		0.50 (0.09 to 0.92)	-49.06 (-89.27 to -7.95)
SIM12 PR24-48 RGT		0.87 (0.78 to 0.94)	-12.40 (-21.57 to -5.71)
SOF24 + RBV (low dose) 24		0.83 (0.18 to 1.02)	-16.38 (-80.89 to 1.45)
PAR/RIT12 + OMB12 + DAS12		1.00 (0.82 to 1.05)	-0.02 (-17.85 to 4.65)
DCV24 + ASU24		0.94 (0.87 to 0.99)	-6.17 (-13.16 to -0.75)
SOF12 + PR12		0.85 (0.29 to 0.98)	-15.07 (-68.21 to -1.56)
B44 PR48		0.76 (0.39 to 0.97)	-23.31 (-59.96 to -3.34)
B24 PR28-48 RGT		0.78 (0.61 to 0.91)	-21.27 (-38.56 to -9.10)
GRZ12 + ELB12		1.00 (0.97 to 1.05)	0.17 (-3.39 to 4.82)
DCV12 + ASU12 + BEC12 + RBV12		0.93 (0.25 to 1.02)	-7.25 (-73.93 to 2.27)
DCV12 + ASU12 + BEC12		0.99 (0.91 to 1.04)	-1.22 (-8.51 to 3.35)
GRZ12 + ELB12 (50 mg q.d.)		0.93 (0.37 to 1.03)	-6.99 (-62.34 to 2.67)
SOF12 + LDV12 + RBV12	SOF8 + LDV8 + RBV8	1.02 (0.95 to 1.91)	1.81 (-4.48 to 46.44)
SOF24 + LDV24 + RBV24		1.02 (0.97 to 1.93)	2.25 (-2.92 to 47.05)
T12 PR24-48 RGT q8		0.87 (0.70 to 1.59)	-12.29 (-28.78 to 30.10)
T12 PR24-48 RGT q12		0.90 (0.67 to 1.63)	-9.62 (-31.26 to 32.83)
T12 PR48 q8		0.54 (0.10 to 1.20)	-43.18 (-86.18 to 12.04)
SIM12 PR24-48 RGT		0.90 (0.80 to 1.65)	-9.32 (-19.70 to 33.14)
SOF24 + RBV (low dose) 24		0.88 (0.19 to 1.70)	-11.67 (-76.86 to 37.23)
PAR/RIT12 + OMB12 + DAS12		1.02 (0.84 to 1.91)	1.98 (-15.00 to 46.41)
DCV24 + ASU24		0.96 (0.88 to 1.79)	-3.52 (-11.70 to 40.00)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + PR12		0.89 (0.31 to 1.55)	-10.01 (-63.97 to 29.57)
B44 PR48		0.81 (0.41 to 1.45)	-18.30 (-56.25 to 24.41)
B24 PR28-48 RGT		0.82 (0.63 to 1.49)	-17.32 (-35.94 to 25.47)
GRZ12 + ELB12		1.03 (0.97 to 1.94)	2.51 (-2.54 to 47.56)
DCV12 + ASU12 + BEC12 + RBV12		0.96 (0.26 to 1.57)	-3.51 (-68.49 to 31.45)
DCV12 + ASU12 + BEC12		1.01 (0.93 to 1.89)	1.11 (-6.83 to 45.26)
GRZ12 + ELB12 (50 mg q.d.)		0.97 (0.39 to 1.75)	-3.08 (-59.20 to 39.06)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.00 (0.97 to 1.06)	0.42 (-3.20 to 5.83)
T12 PR24-48 RGT q8		0.84 (0.69 to 0.94)	-15.19 (-30.41 to -5.59)
T12 PR24-48 RGT q12		0.87 (0.66 to 0.97)	-12.57 (-33.44 to -2.49)
T12 PR48 q8		0.50 (0.09 to 0.92)	-48.30 (-88.88 to -7.36)
SIM12 PR24-48 RGT		0.88 (0.78 to 0.95)	-11.71 (-21.09 to -4.93)
SOF24 + RBV (low dose) 24		0.84 (0.17 to 1.02)	-15.58 (-80.84 to 2.25)
PAR/RIT12 + OMB12 + DAS12		1.01 (0.82 to 1.07)	0.46 (-17.78 to 6.07)
DCV24 + ASU24		0.94 (0.87 to 1.01)	-5.52 (-12.70 to 0.45)
SOF12 + PR12		0.85 (0.29 to 1.00)	-14.40 (-68.17 to -0.04)
B44 PR48		0.77 (0.39 to 0.97)	-22.70 (-59.44 to -2.61)
B24 PR28-48 RGT		0.79 (0.61 to 0.91)	-20.58 (-37.93 to -8.31)
GRZ12 + ELB12		1.01 (0.97 to 1.07)	0.73 (-3.00 to 6.15)
DCV12 + ASU12 + BEC12 + RBV12		0.93 (0.25 to 1.04)	-6.64 (-73.38 to 3.77)
DCV12 + ASU12 + BEC12		0.99 (0.92 to 1.05)	-0.60 (-8.34 to 4.84)
GRZ12 + ELB12 (50 mg q.d.)		0.94 (0.37 to 1.04)	-6.32 (-61.67 to 3.91)
T12 PR24-48 RGT q8	SOF24 + LDV24 + RBV24	0.84 (0.68 to 0.93)	-15.87 (-31.12 to -6.57)
T12 PR24-48 RGT q12		0.87 (0.65 to 0.96)	-13.19 (-34.18 to -3.55)
T12 PR48 q8		0.50 (0.09 to 0.92)	-49.07 (-89.30 to -8.01)
SIM12 PR24-48 RGT		0.87 (0.78 to 0.93)	-12.34 (-21.11 to -6.42)
SOF24 + RBV (low dose) 24		0.83 (0.17 to 1.01)	-16.31 (-80.99 to 1.19)
PAR/RIT12 + OMB12 + DAS12		1.00 (0.82 to 1.03)	0.12 (-17.51 to 2.87)
DCV24 + ASU24		0.94 (0.87 to 0.98)	-6.09 (-13.05 to -1.48)
SOF12 + PR12		0.85 (0.29 to 1.00)	-15.09 (-69.45 to -0.37)
B44 PR48		0.76 (0.39 to 0.97)	-23.28 (-60.21 to -3.19)
B24 PR28-48 RGT		0.78 (0.61 to 0.90)	-21.21 (-38.52 to -9.31)
GRZ12 + ELB12		1.00 (0.97 to 1.04)	0.29 (-3.30 to 3.84)
DCV12 + ASU12 + BEC12 + RBV12		0.93 (0.25 to 1.02)	-7.18 (-73.81 to 2.24)
DCV12 + ASU12 + BEC12		0.99 (0.91 to 1.03)	-1.12 (-8.57 to 2.91)
GRZ12 + ELB12 (50 mg q.d.)		0.93 (0.37 to 1.03)	-7.01 (-61.85 to 2.48)
T12 PR24-48 RGT q12	T12 PR24-48 RGT q8	1.03 (0.86 to 1.16)	2.42 (-10.63 to 11.80)
T12 PR48 q8		0.60 (0.11 to 1.16)	-32.58 (-76.21 to 11.99)
SIM12 PR24-48 RGT		1.04 (0.91 to 1.27)	3.37 (-7.78 to 18.64)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV (low dose) 24		0.99 (0.21 to 1.34)	-0.43 (-65.73 to 23.83)
PAR/RIT12 + OMB12 + DAS12		1.19 (0.96 to 1.46)	15.27 (-3.63 to 31.17)
DCV24 + ASU24		1.12 (1.00 to 1.37)	9.56 (-0.26 to 24.85)
SOF12 + PR12		1.01 (0.35 to 1.30)	0.74 (-53.41 to 21.50)
B44 PR48		0.91 (0.46 to 1.25)	-7.21 (-44.96 to 18.16)
B24 PR28-48 RGT		0.94 (0.73 to 1.18)	-5.26 (-22.89 to 12.47)
GRZ12 + ELB12		1.20 (1.08 to 1.47)	16.15 (7.03 to 31.48)
DCV12 + ASU12 + BEC12 + RBV12		1.09 (0.29 to 1.38)	7.59 (-57.46 to 26.67)
DCV12 + ASU12 + BEC12		1.18 (1.05 to 1.45)	14.45 (4.00 to 29.95)
GRZ12 + ELB12 (50 mg q.d.)		1.10 (0.44 to 1.40)	8.21 (-46.51 to 27.50)
T12 PR48 q8	T12 PR24-48 RGT q12	0.59 (0.10 to 1.15)	-34.77 (-78.67 to 10.83)
SIM12 PR24-48 RGT		1.01 (0.88 to 1.33)	0.72 (-11.12 to 21.37)
SOF24 + RBV (low dose) 24		0.97 (0.21 to 1.36)	-2.63 (-67.46 to 24.69)
PAR/RIT12 + OMB12 + DAS12		1.15 (0.93 to 1.53)	12.57 (-6.29 to 33.95)
DCV24 + ASU24		1.08 (0.96 to 1.43)	7.00 (-3.64 to 27.67)
SOF12 + PR12		0.98 (0.34 to 1.34)	-1.67 (-56.38 to 23.33)
B44 PR48		0.89 (0.45 to 1.26)	-9.44 (-47.53 to 18.40)
B24 PR28-48 RGT		0.91 (0.71 to 1.23)	-7.83 (-25.91 to 14.88)
GRZ12 + ELB12		1.16 (1.04 to 1.54)	13.50 (3.86 to 34.67)
DCV12 + ASU12 + BEC12 + RBV12		1.06 (0.29 to 1.43)	4.83 (-58.96 to 28.71)
DCV12 + ASU12 + BEC12		1.14 (1.01 to 1.52)	11.77 (0.80 to 33.08)
GRZ12 + ELB12 (50 mg q.d.)		1.07 (0.44 to 1.45)	5.62 (-48.21 to 29.71)
SIM12 PR24-48 RGT	T12 PR48 q8	1.74 (0.92 to 9.86)	36.31 (-7.14 to 78.84)
SOF24 + RBV (low dose) 24		1.51 (0.38 to 8.31)	26.67 (-40.35 to 81.51)
PAR/RIT12 + OMB12 + DAS12		1.97 (1.05 to 10.78)	47.82 (3.86 to 88.47)
DCV24 + ASU24		1.87 (1.01 to 10.37)	42.71 (0.72 to 84.15)
SOF12 + PR12		1.61 (0.52 to 8.72)	30.24 (-32.87 to 78.61)
B44 PR48		1.49 (0.59 to 8.27)	23.50 (-32.15 to 73.15)
B24 PR28-48 RGT		1.56 (0.79 to 8.93)	27.37 (-18.30 to 72.27)
GRZ12 + ELB12		2.00 (1.09 to 11.12)	49.28 (7.98 to 89.88)
DCV12 + ASU12 + BEC12 + RBV12		1.70 (0.42 to 9.78)	35.68 (-37.77 to 84.73)
DCV12 + ASU12 + BEC12		1.97 (1.06 to 10.89)	47.38 (5.49 to 88.43)
GRZ12 + ELB12 (50 mg q.d.)		1.76 (0.58 to 9.76)	38.09 (-30.14 to 84.33)
SOF24 + RBV (low dose) 24	SIM12 PR24-48 RGT	0.95 (0.20 to 1.22)	-3.94 (-70.62 to 17.15)
PAR/RIT12 + OMB12 + DAS12		1.14 (0.93 to 1.28)	11.90 (-6.08 to 21.63)
DCV24 + ASU24		1.07 (1.00 to 1.17)	6.17 (0.14 to 13.58)
SOF12 + PR12		0.97 (0.33 to 1.19)	-2.74 (-55.53 to 15.03)
B44 PR48		0.87 (0.44 to 1.14)	-10.85 (-47.89 to 11.27)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
B24 PR28-48 RGT		0.90 (0.70 to 1.06)	-8.64 (-25.47 to 4.44)
GRZ12 + ELB12		1.15 (1.07 to 1.28)	12.63 (6.34 to 21.67)
DCV12 + ASU12 + BEC12 + RBV12		1.06 (0.28 to 1.24)	4.84 (-60.12 to 18.57)
DCV12 + ASU12 + BEC12		1.13 (1.03 to 1.26)	11.03 (2.63 to 20.31)
GRZ12 + ELB12 (50 mg q.d.)		1.06 (0.42 to 1.25)	5.09 (-50.27 to 19.51)
PAR/RIT12 + OMB12 + DAS12	SOF24 + RBV (low dose) 24	1.19 (0.90 to 5.68)	15.75 (-9.79 to 79.35)
DCV24 + ASU24		1.13 (0.91 to 5.39)	10.25 (-9.20 to 74.84)
SOF12 + PR12		1.01 (0.35 to 4.80)	1.24 (-57.61 to 69.99)
B44 PR48		0.94 (0.45 to 4.10)	-5.11 (-51.10 to 60.92)
B24 PR28-48 RGT		0.94 (0.67 to 4.59)	-4.68 (-31.33 to 62.10)
GRZ12 + ELB12		1.20 (0.99 to 5.75)	16.57 (-0.71 to 81.39)
DCV12 + ASU12 + BEC12 + RBV12		1.07 (0.32 to 4.48)	5.78 (-54.01 to 71.08)
DCV12 + ASU12 + BEC12		1.18 (0.97 to 5.60)	14.83 (-3.26 to 78.60)
GRZ12 + ELB12 (50 mg q.d.)		1.09 (0.45 to 5.23)	7.55 (-48.23 to 74.49)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12	0.94 (0.87 to 1.16)	-5.85 (-13.34 to 12.52)
SOF12 + PR12		0.86 (0.29 to 1.08)	-14.10 (-68.57 to 7.16)
B44 PR48		0.77 (0.39 to 1.02)	-22.22 (-59.52 to 1.69)
B24 PR28-48 RGT		0.79 (0.61 to 0.99)	-20.44 (-38.19 to -0.65)
GRZ12 + ELB12		1.00 (0.97 to 1.23)	0.10 (-3.45 to 18.63)
DCV12 + ASU12 + BEC12 + RBV12		0.93 (0.26 to 1.11)	-6.75 (-70.98 to 9.33)
DCV12 + ASU12 + BEC12		0.99 (0.91 to 1.21)	-1.00 (-8.65 to 16.91)
GRZ12 + ELB12 (50 mg q.d.)		0.94 (0.37 to 1.15)	-6.24 (-60.68 to 12.61)
SOF12 + PR12	DCV24 + ASU24	0.90 (0.31 to 1.08)	-8.72 (-62.93 to 7.23)
B44 PR48		0.82 (0.41 to 1.05)	-16.96 (-53.97 to 4.16)
B24 PR28-48 RGT		0.84 (0.65 to 0.97)	-15.00 (-31.77 to -2.57)
GRZ12 + ELB12		1.07 (1.02 to 1.16)	6.35 (1.82 to 13.32)
DCV12 + ASU12 + BEC12 + RBV12		0.99 (0.26 to 1.12)	-1.12 (-67.47 to 10.52)
DCV12 + ASU12 + BEC12		1.05 (0.97 to 1.14)	4.77 (-2.89 to 12.05)
GRZ12 + ELB12 (50 mg q.d.)		0.99 (0.39 to 1.13)	-0.93 (-55.94 to 11.39)
B44 PR48	SOF12 + PR12	0.92 (0.46 to 2.74)	-7.04 (-47.55 to 51.02)
B24 PR28-48 RGT		0.93 (0.69 to 2.68)	-5.73 (-28.89 to 48.46)
GRZ12 + ELB12		1.18 (1.00 to 3.48)	15.27 (0.38 to 70.02)
DCV12 + ASU12 + BEC12 + RBV12		1.06 (0.30 to 3.10)	5.16 (-57.46 to 61.92)
DCV12 + ASU12 + BEC12		1.16 (0.98 to 3.40)	13.43 (-1.97 to 67.62)
GRZ12 + ELB12 (50 mg q.d.)		1.08 (0.45 to 3.18)	6.39 (-46.34 to 61.92)
B24 PR28-48 RGT	B44 PR48	1.03 (0.72 to 2.04)	1.85 (-25.21 to 40.50)
GRZ12 + ELB12		1.32 (1.04 to 2.58)	23.57 (3.63 to 60.25)
DCV12 + ASU12 + BEC12 + RBV12		1.16 (0.33 to 2.31)	12.46 (-51.77 to 53.30)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV12 + ASU12 + BEC12		1.29 (1.01 to 2.53)	21.73 (1.13 to 58.48)
GRZ12 + ELB12 (50 mg q.d.)		1.18 (0.48 to 2.35)	13.63 (-40.85 to 54.26)
GRZ12 + ELB12	B24 PR28-48 RGT	1.28 (1.11 to 1.65)	21.54 (9.78 to 38.66)
DCV12 + ASU12 + BEC12 + RBV12		1.16 (0.32 to 1.55)	12.58 (-51.75 to 33.83)
DCV12 + ASU12 + BEC12		1.26 (1.08 to 1.62)	19.81 (7.18 to 36.96)
GRZ12 + ELB12 (50 mg q.d.)		1.17 (0.47 to 1.56)	13.22 (-41.49 to 34.80)
DCV12 + ASU12 + BEC12 + RBV12	GRZ12 + ELB12	0.92 (0.24 to 1.02)	-7.56 (-74.50 to 1.80)
DCV12 + ASU12 + BEC12		0.99 (0.91 to 1.03)	-1.41 (-8.82 to 2.44)
GRZ12 + ELB12 (50 mg q.d.)		0.93 (0.37 to 1.02)	-7.23 (-61.89 to 1.98)
DCV12 + ASU12 + BEC12	DCV12 + ASU12 + BEC12 + RBV12	1.07 (0.97 to 3.92)	5.92 (-3.33 to 70.48)
GRZ12 + ELB12 (50 mg q.d.)		1.00 (0.43 to 3.76)	0.14 (-52.25 to 67.77)
GRZ12 + ELB12 (50 mg q.d.)	DCV12 + ASU12 + BEC12	0.94 (0.38 to 1.07)	-5.60 (-60.28 to 6.14)
Random effect model	Residual deviance	45.58 vs. 50 data points	
	Deviance information criteria	247.456	
Fixed effect model	Residual deviance	45.25 vs. 50 data points	
	Deviance information criteria	245.819	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.